 |
| Editorial |  Top |
|
 |
|
Why vaccines? p474
Adrian J. Ivinson
doi:10.1038/nm0598supp-474
PDF
(133K)
|
|
| Foreword | Top |
|
|
|
Living up to the legacy pp475 - 476
Sir Gustav Nossal
doi:10.1038/nm0598supp-475
PDF
(241K)
|
|
| News | Top |
|
|
|
New vaccines are aimed at the rich says UNICEF p477
Karen Birmingham
doi:10.1038/nm0598supp-477a
PDF
(141K)
|
|
|
|
Panel recommends White House coordinates AIDS vaccine development pp477 - 478
Karen Birmingham
& Myrna E. Watanabe
doi:10.1038/nm0598supp-477b
PDF
(399K)
|
|
|
|
Deal emphasizes the importance of DNA vaccines p478
Myrna E. Watanabe
doi:10.1038/nm0598supp-478a
PDF
(270K)
|
|
|
|
Reactions to MMR immunization scare pp478 - 479
Karen Birmingham
& Marlene Cimons
doi:10.1038/nm0598supp-478b
PDF
(438K)
|
|
|
|
Slow progress in malaria vaccine development p479
Alan Dove
doi:10.1038/nm0598supp-479
PDF
(417K)
|
|
| Commentaries | Top |
|
|
|
Vaccine visions and their global impact pp480 - 484
Barry R. Bloom
& Roy Widdus
doi:10.1038/nm0598supp-480
Abstract + references | PDF
(586K)
|
|
|
|
For vaccines, the future is now pp485 - 487
Ronald J. Saldarini
doi:10.1038/nm0598supp-485
Abstract | PDF
(395K)
|
|
|
|
Win-win interactions between the public and private sectors pp487 - 491
Amie Batson
doi:10.1038/nm0598supp-487
Abstract | PDF
(538K)
|
|
|
|
The Role of US Government Agencies in Vaccine Research And Development pp491 - 494
Gregory K. Folkers
& Anthony S. Fauci
doi:10.1038/nm0598supp-491
Abstract + references | PDF
(504K)
|
|
|
|
Why do we not have an HIV vaccine and how can we make one? pp495 - 498
Dennis R. Burton
& John P. Moore
doi:10.1038/nm0598supp-495
Abstract + references | PDF
(573K)
|
|
| News and Views | Top |
|
|
|
Slaying the Hydra all at once or head by head? pp499 - 500
Philippe J. Sansonetti
doi:10.1038/nm0598supp-499
Abstract + references | PDF
(251K)
|
|
|
|
Alchemy for asthma pp500 - 501
William O.C.M. Cookson
& Miriam F. Moffatt
doi:10.1038/nm0598supp-500
Abstract + references | PDF
(241K)
|
|
|
|
Pharmaceutical foodstuffs—oral immunization with transgenic plants pp502 - 503
Charles J. Arntzen
doi:10.1038/nm0598supp-502
Abstract + references | PDF
(265K)
|
|
|
|
The global vaccine enterprise : A developing world perspective pp503 - 505
Seung-Il Shin
doi:10.1038/nm0598supp-503
Abstract + references | PDF
(383K)
|
|
|
|
Recruiting HLA to fight HIV p505
Barbara Laumbacher
& Rudolf Wank
doi:10.1038/nm0598supp-505
Abstract + references | PDF
(112K)
|
|
|
|
Vaccine production in russia : An update p506
Kristina S. Westerdahl
& Roger Roffey
doi:10.1038/nm0598supp-506
Abstract + references | PDF
(140K)
|
|
| History | Top |
|
|
|
Six decades of vaccine development—a personal history pp507 - 514
Maurice R. Hilleman
doi:10.1038/nm0598supp-507
References | PDF
(1,190K)
|
|
| Reviews | Top |
|
|
|
Vaccine developments pp515 - 519
Margaret A. Liu
doi:10.1038/nm0598supp-515
Abstract + references | PDF
(679K)
|
|
|
|
Research toward vaccines against malaria pp520 - 524
Louis H. Miller
& Stephen L. Hoffman
doi:10.1038/nm0598supp-520
Abstract + references | PDF
(1,154K)
|
|
|
|
Cancer vaccines pp525 - 531
Drew M. Pardoll
doi:10.1038/nm0598supp-525
Abstract + references | PDF
(2,623K)
|
|
|
|
HIV Vaccines—where are we going? pp532 - 534
Carole A. Heilman
& David Baltimore
doi:10.1038/nm0598supp-532
Abstract + references | PDF
(1,382K)
|
|
|
Top |
|
|
